International Journal of Radiation Oncology * Biology * Physics
Volume 59, Issue 3 , Pages 674-683 , 1 July 2004

Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients

Preliminary results published in part in abstract form (Cozzarini C, et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical prostatectomy: a single institution experience on 410 patients. Int J Radiat Oncol Biol Phys 2002;54(Suppl. 1):63) and reported as an oral presentation during the 44th American Society for Therapeutic Radiology and Oncology Annual Meeting, October 4–8, 2002, New Orleans, LA.

  • Cesare Cozzarini, M.D.

      Affiliations

    • Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    • Corresponding Author InformationReprint requests to: Cesare Cozzarini, M.D., Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, Milan 20132 Italy. Tel: (+39) 02-2643-7649; Fax: (+39) 02-2643-7603
    • ,
  • Angelo Bolognesi, M.D.

      Affiliations

    • Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Giovanni Luca Ceresoli, M.D.

      Affiliations

    • Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Claudio Fiorino, M.D.

      Affiliations

    • Department of Medical Physics, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Alberto Rossa, M.D.

      Affiliations

    • Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Roberto Bertini, M.D.

      Affiliations

    • Department of Urology, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Renzo Colombo, M.D.

      Affiliations

    • Department of Urology, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Luigi Da Pozzo, M.D.

      Affiliations

    • Department of Urology, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Francesco Montorsi, M.D.

      Affiliations

    • Department of Urology, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Marco Roscigno, M.D.

      Affiliations

    • Department of Urology, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Riccardo Calandrino, Ph.D.

      Affiliations

    • Department of Medical Physics, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Patrizio Rigatti, M.D.

      Affiliations

    • Department of Urology, San Raffaele H Scientific Institute, Milan, Italy
    • ,
  • Eugenio Villa, M.D.

      Affiliations

    • Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy

Received 11 June 2003 ,Revised 6 October 2003 ,Accepted 2 December 2003.

References 

  1. Potosky AL, Miller BA, Albertsen PC, et al.  The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–552
  2. Amling CL, Blute ML, Lerner SE, et al.  Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998;73:401–406
  3. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 1998;160:299–315
  4. Cheng L, Darson MF, Bergstralh EJ, et al.  Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer. 1999;86:1775–1782
  5. Cheng CW, Bergstralh EJ, Zincke H. Stage D1 prostate cancer (A nonrandomized comparison of conservative treatment options versus radical prostatectomy). Cancer. 1993;71:996–1004
  6. Austenfeld MS, Davis BE. New concepts in the treatment of stage D1 adenocarcinoma of the prostate. Urol Clin North Am. 1990;17:867–884
  7. Leibovich BC, Engen DE, Patterson DE, et al.  Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000;163:1178–1182
  8. Cheng WS, Frydenberg M, Bergstralh EJ, et al.  Radical prostatectomy for pathologic stage C prostate cancer (Influence of pathologic variables and adjuvant treatment on disease outcome). Urology. 1993;42:283–291
  9. Ohori M, Wheeler TM, Kattan MW, et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995;154:1818–1824
  10. Anscher MS, Robertson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate (Ten-year update). Int J Radiat Oncol Biol Phys. 1995;33:37–43
  11. Petrovich Z, Lieskovsky G, Langholz B, et al.  Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:600–609
  12. Petrovich Z, Lieskovsky G, Langholz B, et al.  Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate. Am J Clin Oncol. 2001;24:537–546
  13. Schild SE, Wong WW, Grado GL, et al.  The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys. 1996;34:535–541
  14. Zietman AL, Coen JJ, Shipley WU, et al.  Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate (Analysis of freedom from PSA failure). Urology. 1993;42:292–298
  15. Morris MM, Dallow KC, Zietman AL, et al.  Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:731–736
  16. Valicenti RK, Gomella LG. Durable efficacy of adjuvant radiation therapy for prostate cancer (Will the benefit last?). Semin Urol Oncol. 2000;18:115–120
  17. Valicenti RK, Gomella LG, Ismail M, et al.  Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:501–506
  18. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology. 1996;47:232–235
  19. Romics I, Wurz U, Bach D. The prognostic value of prostate specific antigen in the follow-up of patients after radical prostatectomy. Int Urol Nephrol. 1995;27:319–324
  20. Sobin LH, Wittekind CH, editors for the International Union Against Cancer (UICC). TNM classification of malignant tumours. 5th ed. New York: Wiley; 1997
  21. Cozzarini C, Fiorino C, Ceresoli GL, et al.  Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy). Int J Radiat Oncol Biol Phys. 2003;55:688–694
  22. Zelefsky MJ, Aschkenasy E, Kelsen S, et al.  Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39:327–333
  23. Cozzarini C, Fiorino C, Mandelli D, et al.  3D conformal radiotherapy significantly reduces toxicity of post-prostatectomy adjuvant of salvage irradiation [Abstract]. Int J Radiat Oncol Biol Phys. 2000;48(Suppl. 1):248
  24. Fiorino C. Set-up error for conformal radiotherapy of prostate cancer. Radiother Oncol. 2000;56:355–356
  25. Marks LB, Carroll PR, Dugan TC, et al.  The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1257–1280
  26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  27. Cox DR. Regression models and life tables. J Roy Stat Soc. 1982;34:187–220
  28. Cadeddu JA, Partin AW, Epstein JI, et al.  Stage D1 (T1-3, N1-3, M0) prostate cancer (A case-controlled comparison of conservative treatment versus radical prostatectomy). Urology. 1997;50:251–255
  29. Steinberg GD, Epstein JI, Piantadosi S, et al.  Management of stage D1 adenocarcinoma of the prostate (The Johns Hopkins experience 1974 to 1987). J Urol. 1990;144:1425–1432
  30. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837–1842
  31. Kausik SJ, Blute ML, Sebo TJ, et al.  Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002;95:1215–1219
  32. Epstein JI. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am. 1996;23:651–663
  33. Vicini FA, Ziaja EL, Kestin LL, et al.  Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999;54:111–117
  34. Choo R, Hruby G, Hong J, et al.  (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002;53:269–276
  35. Suit HD, Westgate SJ. Impact of improved local control on survival. Int J Radiat Oncol Biol Phys. 1986;12:453–458
  36. Zagars GK, von Eschenbach AC, Ayala AG, et al.  The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 1991;68:2370–2377
  37. Coen JJ, Zietman AL, Thakral H, et al.  Radical radiation for localized prostate cancer (Local persistence of disease results in a late wave of metastases). J Clin Oncol. 2002;20:3199–3205
  38. Do TM, Parker RG, Smith RB, et al.  High-grade carcinoma of the prostate (A comparison of current local therapies). Urology. 2001;57:1121–1126
  39. Andriole GL. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Eur Urol. 1997;32(Suppl. 3):65–69
  40. Frazier HA, Robertson JE, Paulson DF. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?. World J Urol. 1994;12:308–312
  41. Frohmuller HG, Theiss M, Manseck A, et al.  Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer (Radical prostatectomy plus androgen deprivation versus androgen deprivation alone). Eur Urol. 1995;27:202–206
  42. Freeman JA, Lieskovsky G, Grossfeld G, et al.  Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate. Urology. 1994;44:719–725
  43. Carter GE, Lieskovsky G, Skinner DG, et al.  Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J Urol. 1989;142:1266–1270
  44. Sidi AA, Lange PH. Adjuvant radiation therapy in patients upstaged to stage C or D1 disease after radical prostatectomy. Eur Urol. 1987;13:238–241
  45. Bahnson RR, Garnett JE, Grayhack JT. Adjuvant radiation therapy in stages C and D1 prostatic adenocarcinoma (Preliminary results). Urology. 1986;27:403–406
  46. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001;58:233–239

PII: S0360-3016(03)02351-4

doi: 10.1016/j.ijrobp.2003.12.001

International Journal of Radiation Oncology * Biology * Physics
Volume 59, Issue 3 , Pages 674-683 , 1 July 2004

Article Tools

* Image Usage & Resolution